Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ.

Cell. 1998 Apr 17;93(2):165-76.

2.

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.

Takahashi N, Udagawa N, Suda T.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. Review.

PMID:
10080918
3.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
4.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

5.

The molecular basis of osteoclast differentiation and activation.

Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N.

Novartis Found Symp. 2001;232:235-47; discussion 247-50. Review.

PMID:
11277084
6.
7.

Osteoclast differentiation and activation.

Boyle WJ, Simonet WS, Lacey DL.

Nature. 2003 May 15;423(6937):337-42. Review.

PMID:
12748652
8.

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL.

J Bone Miner Res. 2000 Jan;15(1):2-12. Review.

9.

[Osteoporosis induced by immunosuppressant].

Fukunaga J, Sugahara T.

Nihon Rinsho. 2004 Feb;62 Suppl 2:740-3. Review. Japanese. No abstract available.

PMID:
15035219
10.

Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.

Hofbauer LC, Heufelder AE.

Eur J Endocrinol. 1998 Aug;139(2):152-4. Review. No abstract available.

11.

Recent advances in osteoclast biology and pathological bone resorption.

Blair HC, Athanasou NA.

Histol Histopathol. 2004 Jan;19(1):189-99. doi: 10.14670/HH-19.189. Review.

PMID:
14702187
12.

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

Hofbauer LC.

Eur J Endocrinol. 1999 Sep;141(3):195-210. Review. No abstract available.

13.

[A new paradigm of osteoclast biology: discovery of OCIF and ODF].

Yasuda H.

Seikagaku. 2000 Jul;72(7):507-25. Review. Japanese. No abstract available.

PMID:
10967683
14.

[Research progress of regulation of osteoclast formation and function].

Yan Y, Lin X, Dai X, Wang G, Zhang L, Zou H.

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2014 Nov;28(11):1435-40. Review. Chinese.

PMID:
25639065

Supplemental Content

Support Center